Peijia Medical's CE Mark Application Submission
Peijia Medical Limited (HKEX: 9996) has taken a significant step in its mission to globalize its medical innovations by formally submitting the CE Mark registration application for its innovative GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System. This device is engineered for treating mitral regurgitation, showcasing a collaborative effort with HighLife SAS, Peijia's strategic partner in Europe.
Milestone for Global Expansion
The submission of the CE Mark is not just a procedural formality; it marks a pivotal moment in Peijia Medical's endeavor to expand its reach in vital international healthcare markets. This application exemplifies the company's unwavering commitment to providing advanced treatment options on a larger scale, reinforcing its position as a leader in the interventional procedural medical device sector.
Innovative Features of GeminiOne
The GeminiOne TEER device represents a fusion of innovative design and technological advancement. Featuring a unique sliding groove mechanism, it allows for an extended coaptation length while ensuring the implant remains compact and efficient. Additionally, its independent leaflet grasping design aims to simplify procedures, enhancing overall efficiency during surgery.
One of the standout characteristics of the GeminiOne system is its auto-locking mechanism, which serves to mitigate operational errors during procedures. Furthermore, the device's multi-angular detachment capability is specifically designed to accommodate varying anatomical structures, making it a versatile tool for surgeons. The entire design has received global patent protections and has passed extensive freedom-to-operate analyses, ensuring a strong foundation for its introduction to the market.
Regulatory Progress and Future Prospects
In conjunction with its European submission, Peijia Medical has also made strides in the Chinese market, where the National Medical Products Administration (NMPA) has accepted the registration application for the GeminiOne system, now undergoing thorough review. In the United States, the system has secured Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (U.S. FDA) to launch an Early Feasibility Study (EFS). These developments highlight Peijia's ongoing dedication to advancing effective treatment for patients dealing with mitral regurgitation.
About Peijia Medical
Established in 2012 and headquartered in Suzhou, China, Peijia Medical has rapidly emerged as a key player in the interventional procedural medical device arena. The company is committed to creating a comprehensive platform that addresses structural heart and neurovascular diseases. With a portfolio that includes four Transcatheter Aortic Valve Replacement (TAVR) systems and almost twenty neurointerventional devices approved in China, Peijia continues to innovate, contributing significantly to the medical field. Their ongoing projects represent not just the future of the company but also the evolution of medical treatment for critical conditions.
Frequently Asked Questions
What is the GeminiOne TEER System?
The GeminiOne TEER System is a medical device designed for the treatment of mitral regurgitation using a novel transcatheter edge-to-edge repair method.
What significance does the CE Mark application hold?
The CE Mark application represents a crucial step for Peijia Medical in establishing its product as compliant with European medical regulations, allowing for market access.
Who is Peijia Medical's partner in Europe?
HighLife SAS serves as Peijia Medical's European partner in the development and marketing of the GeminiOne TEER System.
What are the unique features of the GeminiOne device?
The GeminiOne device features a sliding groove mechanism, independent leaflet grasping design, auto-locking mechanism, and multi-angular detachment capabilities, enhancing its usability in diverse anatomical conditions.
What is the company's goal regarding regulatory approvals?
Peijia Medical aims to swiftly advance its regulatory approvals in both China and Europe, to ensure timely delivery of effective treatment solutions to patients with mitral regurgitation.
